Abstract
It has been suggested that aspirin may be of benefit in treating sepsis and ARDS in view of its ability to block cyclo-oxygenase-1 (COX-1) and COX-2 activities; inhibit nuclear factor kappa B (NF-κB); enhance the production of endothelial nitric oxide (eNO) and lipoxin A4 (LXA4). Our previous studies revealed that plasma phospholipid content of arachidonic acid (AA) and eicosapentaenoic acid (EPA) is low in patients with sepsis. This implies that beneficial actions of aspirin in sepsis and ARDS is unlikely to be obtained in view of deficiency of AA and EPA, the precursors of LXA4 and resolvins respectively that are potent anti-inflammatory compounds and enhancers of eNO generation. In view of this, I propose that a combination of aspirin and AA and EPA (and possibly, docosahexaenoic acid, DHA) is likely to be superior in the management of sepsis and ARDS compared to aspirin alone. This suggestion is supported by the recent observation that trauma patients with uncomplicated recoveries had higher resolvin pathway gene expression and lower gene expression ratios of leukotriene: resolvin pathways.
TY - JOUR
T1 - Combination of aspirin with essential fatty acids is superior to aspirin alone to prevent or ameliorate sepsis or ARDS.
A1 - Das,Undurti N,
Y1 - 2016/11/25/
PY - 2016/07/01/received
PY - 2016/11/15/accepted
PY - 2016/11/27/entrez
PY - 2016/11/27/pubmed
PY - 2017/4/8/medline
KW - Acute respiratory distress syndrome
KW - Arachidonic acid
KW - Aspirin
KW - Cyclo-oxygenase
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - Essential fatty acids
KW - Lipoxin A4
KW - Lipoxygenase
KW - Nitric oxide
KW - Protectins
KW - Resolvin
KW - Sepsis
SP - 206
EP - 206
JF - Lipids in health and disease
JO - Lipids Health Dis
VL - 15
IS - 1
N2 - It has been suggested that aspirin may be of benefit in treating sepsis and ARDS in view of its ability to block cyclo-oxygenase-1 (COX-1) and COX-2 activities; inhibit nuclear factor kappa B (NF-κB); enhance the production of endothelial nitric oxide (eNO) and lipoxin A4 (LXA4). Our previous studies revealed that plasma phospholipid content of arachidonic acid (AA) and eicosapentaenoic acid (EPA) is low in patients with sepsis. This implies that beneficial actions of aspirin in sepsis and ARDS is unlikely to be obtained in view of deficiency of AA and EPA, the precursors of LXA4 and resolvins respectively that are potent anti-inflammatory compounds and enhancers of eNO generation. In view of this, I propose that a combination of aspirin and AA and EPA (and possibly, docosahexaenoic acid, DHA) is likely to be superior in the management of sepsis and ARDS compared to aspirin alone. This suggestion is supported by the recent observation that trauma patients with uncomplicated recoveries had higher resolvin pathway gene expression and lower gene expression ratios of leukotriene: resolvin pathways.
SN - 1476-511X
UR - https://www.unboundmedicine.com/medline/citation/27887602/Combination_of_aspirin_with_essential_fatty_acids_is_superior_to_aspirin_alone_to_prevent_or_ameliorate_sepsis_or_ARDS_
L2 - https://lipidworld.biomedcentral.com/articles/10.1186/s12944-016-0377-2
DB - PRIME
DP - Unbound Medicine
ER -